We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04880460
Recruitment Status : Completed
First Posted : May 10, 2021
Last Update Posted : March 21, 2022
Sponsor:
Information provided by (Responsible Party):
Dr. Sarmin Sultana, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Brief Summary:
A randomized, double-blind, placebo-controlled trial was conducted to assess the effect of magnesium glycinate on symptoms of moderate to severe depression in 90 patients. Patients were assessed at baseline, end of the 4 weeks, and end of the 8 weeks of treatment. Patients were randomized to receive either 200 mg elemental magnesium or 200 mg placebo tablet twice daily for 8 weeks. The primary outcome measure was depression severity score assessment using Depression Anxiety Stress Scale 21 items Bangla Version (DASS-21 BV) and the secondary outcome measure was serum magnesium level estimation and side effects assessment using a preformed checklist.

Condition or disease Intervention/treatment Phase
MDD Dietary Supplement: Magnesium Glycinate tablet 200mg Dietary Supplement: Placebo tablet 200mg Phase 2

Detailed Description:
Major depressive disorder (MDD), is a mood disorder affecting 300 million people worldwide with a prevalence of 6.7% in Bangladesh. Depression is the main contributor to suicidal deaths and is globally ranked as the single largest contributor to non-fatal health loss. Various psychological, genetic, environmental, and biochemical factors are presumed to be involved in the causation of MDD. About 30% to 50% of patients do not respond to initial antidepressant medication, and 15% of them continue to suffer from symptoms despite the completion of multiple antidepressants and more aggressive treatment regimens, in addition to facing untoward adverse drug reactions with increasing dose. Recent trials attempted to assess the effect of magnesium in reducing depressive symptoms in MDD patients. This study evaluates whether there was any role of magnesium in reducing depressive symptoms between those who did and did not receive magnesium in 8 weeks period. Patients attending the Outpatient Department of Psychiatry, BSMMU, and diagnosed with MDD were evaluated using the DASS-21 BV for assessment of severity. Those patients who were experiencing moderate to severe symptoms (scores of 14-27) were enrolled according to inclusion and exclusion criteria. Total enrolled 90 MDD patients who have received either 200 mg elemental magnesium twice daily in the form of magnesium glycinate tablet or 200 mg placebo tablet twice daily for 8 weeks. A baseline depression severity score assessment was done using DASS-21 items and again repeated at the end of the 4 weeks and 8 weeks of treatment. Initially, baseline serum magnesium level (mg/dL) was measured and repeated again at the end of the 8 weeks of treatment. DASS-21 is a validated set of three self-report scales to measure the state of depression, anxiety, and stress, where each of the three scales contains 7 items, and each item is rated from 0 to 3. The depression scale assesses dysphoria, hopelessness, devaluation of life, self-deprecation, lack of interest, anhedonia, and inertia.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: A type of intervention model describing a clinical trial in which two or more groups of participants receive different interventions. For example, a two-arm parallel assignment involves two groups of participants. One group receives drug A, and the other group receives drug B. So during the trial, participants in one group receive drug A "in parallel" to participants in the other group, who receive drug B.
Masking: Double (Participant, Investigator)
Masking Description: A clinical trial design strategy in which one or more parties involved in the trial, such as the investigator or participants, do not know which participants have been assigned which interventions. The type of masking was double-blind masking.
Primary Purpose: Treatment
Official Title: Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
Actual Study Start Date : March 18, 2021
Actual Primary Completion Date : November 21, 2021
Actual Study Completion Date : November 21, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Experimental
45 MDD patients were included in this arm who were received SSRIs and Magnesium tablets
Dietary Supplement: Magnesium Glycinate tablet 200mg
Magnesium glycinate tablet 200mg twice daily orally for 8 weeks along with SSRIs

Placebo Comparator: Control
45 MDD patients were included in this arm who were received SSRIs and placebo tablets
Dietary Supplement: Placebo tablet 200mg
Placebo tablet 200mg twice daily orally for 8 weeks along with SSRIs




Primary Outcome Measures :
  1. Depression severity score assessment [ Time Frame: 8 weeks ]

    Assessed the severity score of depressive symptoms using DASS-21 at baseline, end of the 4 weeks, and end of the 8 weeks treatment.

    Compared the score between before and after treatment. Compared the score between two arms. DASS21 score range from 0-28+ with the following scores: 0-9 Normal, 10-13 Mild, 14-20 Moderate, 21-27 Severe, 28+ Extremely severe.



Secondary Outcome Measures :
  1. Biochemical assessment [ Time Frame: 8 weeks ]

    Serum magnesium level (mg/dL) was measured at baseline and end of the 8 weeks treatment.

    Compared the serum magnesium level (mg/dL) between before and after treatment. Compare the serum magnesium level (mg/dL) between two arms.


  2. Side effects assessment [ Time Frame: 8 weeks ]
    Participants were asked about the side effects using a preformed checklist. And compare the effects between two arms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed 18 years or older MDD patients of both gender according to DSM-5 at the Outpatient Department of Psychiatry, BSMMU
  • Moderate to severe MDD according to DASS-21 (scores of 14-27)
  • Patients prescribed only SSRIs

Exclusion Criteria:

  • Patients having any other psychiatric disease, kidney disease, or gastrointestinal disease
  • Taking dietary supplements in the last two months
  • Taking fluoroquinolones, aminoglycosides, tetracyclines, calcium channel blockers, bisphosphonates, and skeletal muscle relaxants
  • Pregnancy and lactation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04880460


Locations
Layout table for location information
Bangladesh
Basic Science and Paraclinical Science of BSMMU
Dhaka, Bangladesh
Sponsors and Collaborators
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Investigators
Layout table for investigator information
Study Chair: Prof. Md. Sayedur Rahman, MBBS, MPhil, FCPS Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Layout table for additonal information
Responsible Party: Dr. Sarmin Sultana, Principal Investigator, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
ClinicalTrials.gov Identifier: NCT04880460    
Other Study ID Numbers: BSMMU/2021/257
First Posted: May 10, 2021    Key Record Dates
Last Update Posted: March 21, 2022
Last Verified: November 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Dr. Sarmin Sultana, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh:
MDD
Magnesium
DASS-21
Serum magnesium level
Additional relevant MeSH terms:
Layout table for MeSH terms
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders